-- Analysis of drug review times, performance trends, and success rates by therapeutic category, as well as standard versus priority classification
-- The impact of accelerated approval, orphan drug status, and related programs on review times and outcomes
-- Data regarding other key new drug submissions, including NDA resubmissions, efficacy supplements, and manufacturing supplements
PAREXEL's newly-released The US Drug Approval Trends and Yearbook 2008/2009 is the largest compendium of drug approval trends and metrics ever compiled. To order the compendium ($295 USD), visit http://www.barnettinternational.com/EducationalServices/ or email firstname.lastname@example.org. For more PAREXEL book titles published and distributed by Barnett International, a division of Cambridge Healthtech Institute (CHI), visit Barnett Educational Services at http://www.barnettinternational.com/.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical
services organization, providing a broad range of knowledge-based contract
research, medical communications and consulting services to the worldwide
pharmaceutical, biotechnology and medical device industries. Committed to
providing solutions that expedite time-to-market and peak-market
penetration, PAREXEL has developed significant expertise across the
development and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials management,
medical education and reimbursement. Perceptive Informatics, Inc., a
subsidiary of PAREXEL, provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston, Massachusetts, PAREXEL operates in 69 locations
throughout 52 count
|SOURCE PAREXEL International Corporation|
Copyright©2008 PR Newswire.
All rights reserved